Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics, Inc. (CYTH) is a clinical-stage biotechnology company dedicated to developing cyclodextrin-based treatments for neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company was originally organized in 1990 and began operations in 1992. Over the years, Cyclo Therapeutics has evolved into a holding company operating under various subsidiaries, including CTD, Inc.; Nanosonic Products, Inc.; Sphingo Biotech, Inc.; and Ferrazo Environmental Technologies, Inc.
The company's flagship product, Trappsol Cyclo, is at the forefront of its clinical trials for NPC treatment. Cyclo Therapeutics is committed to advancing this promising treatment through various phases of clinical testing, aiming to bring it to market to provide relief for NPC patients.
In addition to its focus on rare diseases, Cyclo Therapeutics generates revenue from the sale of cyclodextrins and related products to pharmaceutical and nutritional industries. Key products include Trappsol HPB and Trappsol Fine Chemical, which are widely used in various industries.
Recent Achievements:
- Successfully completed Phase I clinical trials for Trappsol Cyclo.
- Expanded partnerships with pharmaceutical companies for cyclodextrin-based product development.
- Enhanced research and development capabilities through strategic collaborations.
Cyclo Therapeutics' commitment to innovation and its strategic approach to product development and commercialization have positioned it as a significant player in the biotechnology sector. The company remains focused on its mission to develop effective treatments for rare and neurodegenerative diseases.
Cyclo Therapeutics (Nasdaq: CYTH) announced that Dr. Lise Kjems will present at the World Orphan Drug Congress USA 2022 from July 11-13, 2022, in Boston, MA. Her talk, titled From Bench to Bedside - A Review of the Trappsol Cyclo Program for the Treatment of Niemann Pick Disease Type C, is scheduled for July 13 at 3:45 PM ET. The session will cover the company’s Trappsol® Cyclo™ formulation and its clinical program targeting this rare genetic disease. The presentation will be available on the company's website following the event.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that Professor Caroline Hastings, MD, will present at the 2022 NPC Conference on June 23-24, 2022. Dr. Hastings will discuss the proprietary formulation Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C. The session includes updates from Phase I and II studies and the launch of the Phase III pivotal TransportNPC trial. The conference aims to address the urgent need for treatments for NPC patients globally. A live webcast will be available for registered attendees.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022 in Miami, FL, and virtually. Management will be available for one-on-one meetings with registered investors. A video webcast of the presentation will be available on demand starting May 24, 2022, at 7:00 AM ET. Cyclo Therapeutics focuses on developing medicines for rare diseases.
Cyclo Therapeutics (CYTH) reported Q1 2022 financial results, including a net loss of approximately $2.8 million. The company is advancing its lead program, Trappsol® Cyclo™, in a pivotal Phase 3 study for Niemann-Pick Disease Type C1 (NPC1) and plans to initiate a Phase 2 study for Alzheimer's Disease this year. Recent collaborations with the University of the Witwatersrand aim to expand the use of Trappsol® Cyclo™. Research and development expenses decreased by 67% to $1.1 million, while prepaid clinical expenses rose by $1.4 million. Cash reserves stand at $11.8 million.
Cyclo Therapeutics (NASDAQ: CYTH) will participate in a Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight event on May 16, 2022, at 2:00 PM ET. The company will discuss NPC, a rare genetic disorder and the development of Trappsol® Cyclo™, a treatment showing promising results in clinical studies. Key executives will join Professor Caroline Hastings, the Global Principal Investigator for the ongoing TransportNPC™ study. Cyclo Therapeutics has received Orphan Drug Designation for Trappsol® Cyclo™ in the U.S. and EU.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced its participation in the Virtual Investor Alzheimer’s Disease Spotlight event on April 5, 2022, at 1:00 PM ET. The company's management, including CEO N. Scott Fine and CMO Lise Lund Kjems, will engage in a fireside chat with key opinion leader Cynthia A. Lemere, PhD. Cyclo Therapeutics will discuss its Trappsol® Cyclo™ program for Alzheimer’s treatment, which has recently received FDA clearance for a Phase 2 study targeting early Alzheimer’s disease. The webcast will also be available for replay.
Cyclo Therapeutics (NASDAQ: CYTH) announced a research collaboration with the University of the Witwatersrand in Johannesburg to explore its proprietary Trappsol® Cyclo™ platform technology. This partnership will enhance the development of Cyclo's ongoing Phase 3 study for Niemann-Pick Disease Type C and a planned Phase 2 study for early Alzheimer’s disease. The agreement aims to advance scientific knowledge and expand Cyclo's intellectual property estate. The collaboration emphasizes the strategic importance of leveraging Wits' research capabilities for innovative therapeutic applications.
Cyclo Therapeutics, a clinical-stage biotechnology company, announced its participation in the 2022 Virtual Growth Conference hosted by Maxim Group from
Cyclo Therapeutics (NASDAQ: CYTH) reported significant advancements in its clinical programs, particularly for Trappsol® Cyclo™ targeting Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Disease. The ongoing Phase 3 study, TransportNPC™, aims to provide the first FDA-approved therapy for NPC. In 2021, the company faced a net loss of approximately $14.3 million, with R&D expenses increasing by 50% to $9.2 million due to heightened clinical activity. As of year-end, Cyclo held $16.6 million in cash and anticipates further R&D cost increases in 2022 as it progresses its clinical studies.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) has announced a presentation by CEO N. Scott Fine at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 PM ET. The event includes a live video webcast and opportunities for virtual one-on-one meetings with investors.
The company is focused on developing treatments for rare diseases, particularly Niemann-Pick Disease Type C, with its Trappsol® Cyclo™ drug currently undergoing multiple clinical trials.
FAQ
What is the current stock price of Cyclo Therapeutics (CYTH)?
What is the market cap of Cyclo Therapeutics (CYTH)?
What does Cyclo Therapeutics, Inc. specialize in?
What is Trappsol Cyclo?
When was Cyclo Therapeutics founded?
What are some of Cyclo Therapeutics' key products?
What are the subsidiaries of Cyclo Therapeutics?
Where does Cyclo Therapeutics generate its revenue from?
What recent achievements has Cyclo Therapeutics accomplished?
What is the focus of Cyclo Therapeutics' research?
How does Cyclo Therapeutics contribute to healthcare?
What is the significance of cyclodextrins in Cyclo Therapeutics' products?
